Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Colossal Biosciences

Colossal Biosciences raises $120M Series at $800M valuation

$120M
Total Raised
Series
Latest Round
2021
Founded
100+
Employees
Austin, TX
Updated September 27, 2025
1 min read

Quick Facts

Valuation
$800M
Latest Round Size
$120M
Latest Round Date
September 2025

Colossal Biosciences: Series Funding Round

Colossal Biosciences has successfully raised $120M in Series funding, reaching a valuation of $800M.

Company Overview

Working on de-extinction of species including mammoths and dodos

Funding Details

The Series round was led by CIA In-Q-Tel, with participation from Breyer Capital.

Company Information

  • Headquarters: Austin, TX
  • Founded: 2021
  • Employees: 100+
  • Category: Biotech

Investment

Colossal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • CIA In-Q-Tel: Verified investor in Series
  • Breyer Capital: Verified investor in Series

Key Investors

CIA In-Q-Tel
Lead Investor
Verified investor in Series
Breyer Capital
Investor
Verified investor in Series

Topics

verified(3079)real-funding(3079)colossal-biosciencesbiotechseriesaustin

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M